slc12a9 Antibody

What is SLC12A9 and what is its biological role in cellular function?

SLC12A9 (Solute Carrier Family 12 Member 9) is a protein involved in potassium/chloride transport mechanisms. It functions primarily as an inhibitor of SLC12A1 and appears to be a subunit of a multimeric transport system, suggesting additional subunits may be required for its complete functionality . The protein is also known by several synonyms including cation-chloride cotransporter 6 (hCCC6) and cation-chloride cotransporter-interacting protein 1 . SLC12A9 is involved in maintaining cellular homeostasis through its role in ion transport, which makes it a significant component in cellular physiology studies . The canonical human SLC12A9 protein has a reported length of 914 amino acid residues with a molecular mass of approximately 96.1 kDa and is primarily localized in the cell membrane .

In which experimental applications can SLC12A9 antibodies be reliably used?

SLC12A9 antibodies have been validated for multiple experimental applications, depending on the specific antibody selected. Common applications include:

• Western Blotting (WB): For detection of SLC12A9 protein in cell or tissue lysates

• Immunofluorescence (IF): For visualization of SLC12A9 localization in cells

• Immunohistochemistry (IHC): For detection in tissue sections

• Immunoprecipitation (IP): For isolation of SLC12A9 and associated proteins

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative analysis

The choice of application should be guided by the validation data provided by manufacturers, as not all antibodies perform optimally across all techniques. For instance, the SLC12A9 polyclonal antibody (PACO40738) has been specifically validated for ELISA and IF applications with recommended dilutions of 1:2000-1:10000 for ELISA and 1:50-1:200 for IF .

What tissue expression patterns does SLC12A9 exhibit and how does this inform antibody selection?

SLC12A9 demonstrates tissue-specific expression patterns that researchers should consider when designing experiments. It is highly expressed in placenta, brain, and kidney tissues . This expression profile has implications for experimental design, particularly when selecting positive control tissues or cell lines. When working with SLC12A9 antibodies, researchers should consider using cell lines known to express the protein, such as MCF-7 cells, which have been successfully used in immunofluorescence studies with the PACO40738 antibody . Understanding the natural expression pattern helps in validating antibody specificity and interpreting experimental results, especially when examining tissues where SLC12A9 is expected to be either abundant or scarce.

What are the optimal protocols for Western blot analysis using SLC12A9 antibodies?

For optimal Western blot results with SLC12A9 antibodies, researchers should consider the following methodological approach:

• Sample preparation: Extract proteins using a buffer containing protease inhibitors to prevent degradation of SLC12A9 (MW: ~96.1 kDa).

• Gel selection: Use 8-10% polyacrylamide gels due to the relatively high molecular weight of SLC12A9.

• Transfer conditions: Employ wet transfer methods for proteins of this size, preferably overnight at low voltage (30V) or 2 hours at higher voltage (100V) with cooling.

• Blocking: Block membranes with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute SLC12A9 antibody according to manufacturer recommendations (typically between 1:500-1:2000) and incubate overnight at 4°C .

• Secondary antibody: Select appropriate species-specific secondary antibody based on the host species of the primary antibody (e.g., anti-mouse for ABIN967843 or anti-rabbit for PACO40738) .

• Detection: Use enhanced chemiluminescence (ECL) for visualization, with exposure times adjusted based on signal strength.

• Controls: Include positive controls from tissues known to express SLC12A9 (placenta, brain, or kidney) and negative controls (tissues with low expression or knockout samples).

How should immunofluorescence experiments with SLC12A9 antibodies be optimized?

Optimizing immunofluorescence experiments with SLC12A9 antibodies requires attention to several key parameters:

• Cell fixation: Use 4% paraformaldehyde for 15 minutes at room temperature to preserve cellular structures while maintaining epitope accessibility.

• Permeabilization: Apply 0.1-0.2% Triton X-100 for 10 minutes to allow antibody access to membrane-bound SLC12A9.

• Blocking: Block with 5% normal serum (from the same species as the secondary antibody) with 1% BSA for 1 hour to reduce background.

• Antibody dilution: For SLC12A9 antibodies like PACO40738, use dilutions between 1:50-1:200 as recommended for immunofluorescence applications .

• Incubation conditions: Incubate primary antibody overnight at 4°C in a humidified chamber to enhance specific binding.

• Secondary antibody selection: For optimal results, use fluorophore-conjugated secondary antibodies matching the host species of the primary antibody (e.g., Alexa Fluor 488-conjugated AffiniPure Goat Anti-Rabbit IgG for rabbit polyclonal antibodies) .

• Cell lines: Consider using MCF-7 cells as positive controls, which have demonstrated successful staining with SLC12A9 antibodies in published protocols .

• Confocal microscopy settings: Adjust laser power and detector gain to optimize signal-to-noise ratio without introducing artifacts.

• Colocalization studies: Combine with cellular compartment markers to confirm membrane localization of SLC12A9.

What quality control measures ensure reliable results when working with SLC12A9 antibodies?

Implementing rigorous quality control measures is crucial for generating reproducible and reliable results with SLC12A9 antibodies:

• Antibody validation: Verify antibody specificity through multiple methods, such as Western blot, knock-down/knock-out controls, and peptide competition assays.

• Batch consistency: Document lot numbers and compare performance across different batches of the same antibody.

• Positive and negative controls: Include tissues or cell lines with known SLC12A9 expression profiles (e.g., placenta, brain, and kidney as positive controls) .

• Titration experiments: Perform antibody titration experiments to determine optimal concentration for each application, following manufacturer recommendations (e.g., 1:2000-1:10000 for ELISA, 1:50-1:200 for IF) .

• Secondary antibody controls: Include secondary-only controls to assess non-specific binding.

• Preabsorption controls: When possible, preabsorb the antibody with its immunizing peptide to confirm specificity.

• Cross-reactivity assessment: Verify species reactivity claims and test for cross-reactivity with related proteins, particularly other SLC12A family members.

• Storage conditions: Follow proper storage guidelines to maintain antibody integrity (-20°C with 50% glycerol, or as specified by the manufacturer) .

• Documentation: Maintain detailed records of all quality control procedures for reproducibility and troubleshooting.

How can SLC12A9 antibodies be utilized in cancer research based on recent findings?

Recent studies have identified significant associations between SLC12A9 and colorectal cancer (CRC), offering multiple applications for SLC12A9 antibodies in cancer research:

• Diagnostic biomarker assessment: SLC12A9 antibodies can be employed in the evaluation of SLC12A9 as a diagnostic biomarker for CRC. Studies have demonstrated that SLC12A9 is significantly upregulated in CRC compared to normal tissue, with an AUC of 0.78 (95% CI: 0.74-0.82), sensitivity of 0.92 (95% CI: 0.83-0.96), and specificity of 0.74 (95% CI: 0.69-0.78) .

• Prognostic indicator studies: Researchers can use SLC12A9 antibodies to investigate the correlation between SLC12A9 expression and patient outcomes. Data indicate that patients with overexpressed SLC12A9 have worse prognosis in CRC .

• Clinical correlation analyses: SLC12A9 expression has been linked to specific clinical characteristics including age, pathologic N stage, pathologic M stage, lymphatic invasion, and pathologic stage (p < 0.05), suggesting applications in stratifying patients and understanding disease progression .

• Therapeutic target assessment: As dysregulation of SLC transporters holds potential for targeted therapies, SLC12A9 antibodies can help evaluate the protein's potential as a therapeutic target in preclinical models.

• Combination with single-cell techniques: SLC12A9 antibodies can be incorporated into single-cell analyses to understand the heterogeneity of expression across different cell populations within tumors .

• Immune infiltration studies: Given the observed correlations between SLC12A9 and immune cell infiltration, antibodies can be used to investigate the relationship between SLC12A9 expression and the tumor immune microenvironment .

What approaches can be used to study SLC12A9 interactions with other proteins?

Understanding SLC12A9's interactions with other proteins is critical for elucidating its function as part of a multimeric transport system. Several methodological approaches can be employed:

• Co-immunoprecipitation (Co-IP): Using SLC12A9 antibodies validated for immunoprecipitation (such as ABIN967843) to pull down SLC12A9 and identify interacting partners through subsequent mass spectrometry analysis.

• Proximity ligation assay (PLA): Combining SLC12A9 antibodies with antibodies against suspected interaction partners to visualize protein-protein interactions in situ with single-molecule resolution.

• FRET/BRET analysis: Utilizing fluorescent or bioluminescent fusion proteins in combination with immunofluorescence techniques to detect direct protein interactions in living cells.

• Yeast two-hybrid screening: Complementing antibody-based approaches with genetic screening methods to identify novel interaction partners.

• Cross-linking studies: Applying chemical cross-linkers prior to immunoprecipitation with SLC12A9 antibodies to stabilize transient interactions.

• GST pull-down assays: Using recombinant SLC12A9 fragments to identify domain-specific interactions, followed by verification with antibody-based methods.

• Bimolecular fluorescence complementation (BiFC): Combining with microscopy techniques to visualize the subcellular localization of protein complexes involving SLC12A9.

• Proteomic analysis: Large-scale approaches combining immunoprecipitation with mass spectrometry to identify the SLC12A9 interactome under different physiological conditions.

How can single-cell analysis techniques be combined with SLC12A9 antibodies for advanced research applications?

Integrating SLC12A9 antibodies with single-cell technologies offers powerful approaches for understanding cellular heterogeneity and function:

• Single-cell immunofluorescence: Optimized SLC12A9 antibody protocols can be applied to visualize expression patterns at the single-cell level, revealing heterogeneity within tissues that might be masked in bulk analyses.

• Mass cytometry (CyTOF): Metal-conjugated SLC12A9 antibodies can be used in CyTOF panels to simultaneously measure SLC12A9 expression alongside dozens of other proteins at single-cell resolution.

• Single-cell Western blotting: Microfluidic platforms combined with SLC12A9 antibodies enable protein expression analysis in individual cells, allowing correlation with morphological features.

• Multiparametric flow cytometry: Fluorophore-conjugated SLC12A9 antibodies can be incorporated into flow cytometry panels for high-throughput single-cell analysis and sorting of SLC12A9-expressing cell populations.

• Spatial transcriptomics correlation: SLC12A9 immunostaining can be paired with spatial transcriptomics to correlate protein expression with transcriptional profiles in the tissue context.

• Pseudo-time series analysis: As demonstrated in recent research, SLC12A9 antibodies can be used in conjunction with trajectory inference methods (such as those implemented in the monocle2 package with DDRTree algorithm) to map developmental trajectories and dynamic expression patterns .

• Single-cell proteomics: Emerging technologies combining antibody-based detection with mass spectrometry at the single-cell level can reveal proteomic landscapes including SLC12A9 expression patterns.

What are common challenges when working with SLC12A9 antibodies and how can they be addressed?

Researchers may encounter several challenges when working with SLC12A9 antibodies, which can be addressed through systematic troubleshooting:

• High background in immunostaining:

  • Cause: Insufficient blocking or non-specific binding

  • Solution: Increase blocking time/concentration, optimize antibody dilution, include additional washing steps, or use alternative blocking agents (BSA, normal serum, or commercial blockers)

• Weak or absent signal in Western blotting:

  • Cause: Protein degradation, insufficient transfer, or low expression

  • Solution: Add protease inhibitors during sample preparation, optimize transfer conditions for high molecular weight proteins (~96 kDa), increase antibody concentration, or extend exposure time

• Multiple bands in Western blot:

  • Cause: Post-translational modifications (like glycosylation, which has been reported for SLC12A9 ), protein degradation, or non-specific binding

  • Solution: Include deglycosylation treatments, optimize sample preparation to reduce degradation, or validate bands with knockout/knockdown controls

• Inconsistent results across experiments:

  • Cause: Antibody variability between lots or application-specific optimizations

  • Solution: Document lot numbers, maintain consistent protocols, and perform validation for each new antibody batch

• Cross-reactivity with other SLC12A family members:

  • Cause: Sequence homology between family members

  • Solution: Perform peptide competition assays, include knockout controls, or use antibodies targeting unique regions of SLC12A9

• Suboptimal fixation affecting epitope accessibility:

  • Cause: Overfixation masking epitopes or underfixation causing protein loss

  • Solution: Optimize fixation time and conditions; consider alternative fixatives or antigen retrieval methods

• Sodium azide interference:

  • Cause: Some SLC12A9 antibodies contain sodium azide as a preservative

  • Solution: Be aware that sodium azide can yield toxic hydrazoic acid under acidic conditions and interfere with HRP-based detection systems; dilute waste containing azide compounds in running water before disposal

How should contradictory findings regarding SLC12A9 expression be interpreted and resolved?

When faced with contradictory findings regarding SLC12A9 expression, researchers should adopt a systematic approach to interpretation and resolution:

What statistical approaches are recommended for analyzing SLC12A9 expression data in diagnostic and prognostic applications?

For robust analysis of SLC12A9 expression data in diagnostic and prognostic applications, the following statistical approaches are recommended:

How might SLC12A9 antibodies contribute to personalized medicine approaches in cancer treatment?

SLC12A9 antibodies hold significant potential for advancing personalized medicine in cancer treatment through several innovative applications:

• Companion diagnostic development: SLC12A9 antibodies could be developed into immunohistochemistry-based companion diagnostics to identify patients likely to respond to targeted therapies directed at ion transport mechanisms.

• Patient stratification tools: Given the correlation between SLC12A9 expression and clinical characteristics in colorectal cancer (including pathologic stage, lymphatic invasion, and metastasis) , antibody-based assays could help stratify patients for different treatment regimens.

• Therapeutic response monitoring: Periodic assessment of SLC12A9 expression using antibody-based methods during treatment could help monitor therapeutic efficacy and detect emerging resistance.

• Liquid biopsy developments: SLC12A9 antibodies might be incorporated into circulating tumor cell detection systems or extracellular vesicle capture methods to enable non-invasive monitoring.

• Theranostic applications: Conjugating SLC12A9 antibodies with imaging agents or therapeutic payloads could enable simultaneous diagnosis and treatment of cancers overexpressing this transporter.

• Combination therapy guidance: Understanding the relationship between SLC12A9 expression and other molecular targets could inform rational combination therapies, with antibody-based assays providing the necessary expression data.

• Immune checkpoint integration: As research has indicated connections between SLC12A9 and immune cell infiltration , combining SLC12A9 analysis with immune checkpoint assessment could refine immunotherapy patient selection.

• Prognostic nomogram improvement: Incorporation of antibody-based SLC12A9 quantification into prognostic nomograms could enhance survival prediction accuracy, as demonstrated by nomograms predicting 1, 3, and 5-year survival rates .

What are the latest methodological advances in using SLC12A9 antibodies for multiplexed protein detection?

Recent technological advances have expanded the capabilities of SLC12A9 antibodies for multiplexed protein detection:

• Multiplex immunofluorescence (mIF): Advanced mIF techniques using spectral unmixing allow simultaneous detection of SLC12A9 alongside multiple other proteins, enabling comprehensive characterization of its expression in relation to other biomarkers and cellular contexts.

• Imaging mass cytometry (IMC): Metal-tagged SLC12A9 antibodies can be integrated into IMC panels that simultaneously visualize 40+ proteins at subcellular resolution in tissue sections, providing unprecedented insights into spatial relationships.

• Digital spatial profiling (DSP): This technology combines immunofluorescence imaging with digital counting of oligonucleotide-tagged antibodies, allowing quantitative measurement of SLC12A9 alongside hundreds of other proteins with spatial context preservation.

• Single-cell proteomics platforms: Emerging technologies enable antibody-based detection of SLC12A9 and other proteins at single-cell resolution, revealing cellular heterogeneity that might be masked in bulk analyses.

• Proximity extension assays (PEA): These homogeneous immunoassays use paired antibodies linked to DNA oligonucleotides, enabling highly specific detection of SLC12A9 in multiplexed panels containing hundreds of other proteins from minute sample volumes.

• Tissue microarray (TMA) automation: Advanced TMA platforms combined with automated image analysis allow high-throughput screening of SLC12A9 expression across hundreds of patient samples simultaneously.

• In situ sequencing with antibody detection: These emerging methods combine the spatial resolution of immunohistochemistry with the multiplexing capability of next-generation sequencing to detect SLC12A9 alongside gene expression profiles.

• Quantum dot-based multiplexing: Using quantum dots with narrow emission spectra as antibody labels enables simultaneous detection of SLC12A9 with multiple other targets without spectral overlap challenges.

How can SLC12A9 antibodies be integrated with computational biology approaches for systems-level analysis?

The integration of SLC12A9 antibody-based data with computational biology approaches enables systems-level analysis through several methodological frameworks:

• Pseudo-time trajectory inference: As demonstrated in recent research, SLC12A9 expression data from antibody-based detection can be integrated with computational algorithms like monocle2 using DDRTree methods to reconstruct developmental trajectories and dynamic expression patterns in complex biological systems .

• Network analysis integration: Protein interaction data derived from SLC12A9 antibody-based co-immunoprecipitation experiments can be incorporated into protein-protein interaction networks to identify functional modules and pathway connections.

• Multi-omics data integration: SLC12A9 protein expression data from antibody-based detection can be combined with transcriptomic, genomic, and metabolomic data through computational frameworks that identify cross-platform correlations and causality relationships.

• Machine learning classification models: Quantitative data from SLC12A9 immunohistochemistry or other antibody-based applications can serve as features in machine learning algorithms for disease classification, progression prediction, or treatment response forecasting.

• Digital pathology image analysis: Convolutional neural networks can be trained on SLC12A9 immunohistochemistry images to automatically quantify expression levels, cellular localization patterns, and associations with morphological features.

• Systems pharmacology models: SLC12A9 expression data can be incorporated into mathematical models predicting drug responses, especially for compounds targeting ion transport mechanisms.

• Cellular heterogeneity deconvolution: Computational methods can use SLC12A9 antibody-based single-cell data to deconvolute bulk tissue expression profiles, estimating cellular composition and state transitions.

• Causal inference frameworks: Bayesian networks incorporating SLC12A9 expression data from antibody-based detection can infer causal relationships between transporter activity and downstream cellular phenotypes.